A Phase 1 interventional study of Empagliflozin/linagliptin/metformin HCl and Empagliflozin in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-05.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To establish the bioequivalence of one fixed dose combination (FDC) tablet of empagliflozin/linagliptin/metformin extended release (XR) versus the free combination of empagliflozin tablet, linagliptin tablet, and metformin XR tablets administered as a single dose under fed conditions
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
High dose empagliflozin/linagliptin/metformin XR fixed dose combination tablet
Drug: Empagliflozin/linagliptin/metformin HCl
Single tablets of empagliflozin + linagliptin + metformin XR
Drug: Empagliflozin · Drug: Linagliptin · Drug: Metformin HCl
Drug pages: Empagliflozin · Linagliptin · Metformin
Once daily
Also known as: TRIJARDY® XR
Once daily
Once daily
Once daily
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) for Empagliflozin
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) for empagliflozin. Plasma concentrations and/or parameters of a subject were to be considered as non-evaluable,if for example: * The subject experienced emesis that occurred at or before 2 times median tmax of the respective treatment (median tmax was to be determined excluding the subjects experiencing emesis) * A predose concentration was \>5% Cmax value of that subject * Missing samples/concentration data at important phases of pharmacokinetic (PK) disposition curve. Pharmacokinetic parameter set (PKS): This subject set included all subjects in the treated set (TS) who provided at least one primary or secondary PK parameter that was not excluded according to the description above. Thus, a subject was to be included in the PKS even if he/she contributed only one PK parameter value for one period to the statistical assessment.
Time frame: Pharmacokinetic samples were collected at 1:30 hours: minutes pre dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 hours:minutes post dose
AUC0-tz for Metformin.
AUC0-tz for metformin.
Time frame: Pharmacokinetic samples were collected at 1:30 hours: minutes pre dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 hours:minutes post dose
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72) for Linagliptin
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 72 hours (AUC0-72) for Linagliptin
Time frame: Pharmacokinetic samples were collected at 1:30 hours: minutes pre dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 hours:minutes post dose
Maximum Measured Concentration of the Empagliflozin in Plasma (Cmax)
Maximum measured concentration of the empagliflozin in plasma (Cmax)
Time frame: Pharmacokinetic samples were collected at 1:30 hours: minutes pre dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 hours:minutes post dose
Cmax for Metformin in Plasma
Cmax for metformin in plasma.
Time frame: Pharmacokinetic samples were collected at 1:30 hours: minutes pre dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 hours:minutes post dose
Cmax for Linagliptin in Plasma
Cmax for linagliptin in plasma.
Time frame: Pharmacokinetic samples were collected at 1:30 hours: minutes pre dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 hours:minutes post dose
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity) for Empagliflozin (AUC(0-∞)
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for Empagliflozin (AUC(0-∞)
Time frame: Pharmacokinetic samples were collected at 1:30 hours: minutes pre dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 hours:minutes post dose
AUC(0-∞) for Metformin
AUC(0-∞) for Metformin
Time frame: Pharmacokinetic samples were collected at 1:30 hours: minutes pre dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 hours:minutes post dose
AUC(0-∞) for Linagliptin
AUC(0-∞) for Linagliptin
Time frame: Pharmacokinetic samples were collected at 1:30 hours: minutes pre dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 hours:minutes post dose
It was planned to include healthy male and female subjects in this randomised, open label study. They were recruited from the volunteers' pool of the study site.
| Milestone | Test/ Reference (TR) | Reference/ Test (RT) |
|---|---|---|
| Started | 15 | 15 |
| Completed | 15 | 14 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | Test/ Reference (TR) | Reference/ Test (RT) |
|---|---|---|
| Started | 15 | 14 |
| Completed | 14 | 14 |
| Not completed | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) for empagliflozin. Plasma concentrations and/or parameters of a subject were to be considered as non-evaluable,if for example: * The subject experienced emesis that occurred at or before 2 times median tmax of the respective treatment (median tmax was to be determined excluding the subjects experiencing emesis) * A predose concentration was \>5% Cmax value of that subject * Missing samples/concentration data at important phases of pharmacokinetic (PK) disposition curve. Pharmacokinetic parameter set (PKS): This subject set included all subjects in the treated set (TS) who provided at least one primary or secondary PK parameter that was not excluded according to the description above. Thus, a subject was to be included in the PKS even if he/she contributed only one PK parameter value for one period to the statistical assessment.
| nanomoles*hours/ litres (nmol*h/L) | Empagliflozin/Linagliptin/Metformin FDC (Test) | Empagliflozin/Linagliptin/Metformin FC (Reference) |
|---|---|---|
| Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) for Empagliflozin | 5656.07 ± 1.04 | 5488.31 ± 1.04 |
AUC0-tz for metformin.
| nanogram*hours/ millilitres (ng*h/mL) | Empagliflozin/Linagliptin/Metformin FDC (Test) | Empagliflozin/Linagliptin/Metformin FC (Reference) |
|---|---|---|
| AUC0-tz for Metformin. | 12455.82 ± 1.05 | 12412.57 ± 1.05 |
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 72 hours (AUC0-72) for Linagliptin
| nmol*h/L | Empagliflozin/Linagliptin/Metformin FDC (Test) | Empagliflozin/Linagliptin/Metformin FC (Reference) |
|---|---|---|
| Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72) for Linagliptin | 238.84 ± 1.04 | 238.11 ± 1.04 |
Maximum measured concentration of the empagliflozin in plasma (Cmax)
| nmol/L | Empagliflozin/Linagliptin/Metformin FDC (Test) | Empagliflozin/Linagliptin/Metformin FC (Reference) |
|---|---|---|
| Maximum Measured Concentration of the Empagliflozin in Plasma (Cmax) | 540.01 ± 1.04 | 540.26 ± 1.04 |
Cmax for metformin in plasma.
| ng/mL | Empagliflozin/Linagliptin/Metformin FDC (Test) | Empagliflozin/Linagliptin/Metformin FC (Reference) |
|---|---|---|
| Cmax for Metformin in Plasma | 1237.16 ± 1.04 | 1147.88 ± 1.04 |
Cmax for linagliptin in plasma.
| nmol/L | Empagliflozin/Linagliptin/Metformin FDC (Test) | Empagliflozin/Linagliptin/Metformin FC (Reference) |
|---|---|---|
| Cmax for Linagliptin in Plasma | 5.69 ± 1.04 | 5.86 ± 1.04 |
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for Empagliflozin (AUC(0-∞)
| nmol*h/L | Empagliflozin/Linagliptin/Metformin FDC (Test) | Empagliflozin/Linagliptin/Metformin FC (Reference) |
|---|---|---|
| Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity) for Empagliflozin (AUC(0-∞) | 5727.20 ± 1.04 | 5554.37 ± 1.04 |
AUC(0-∞) for Metformin
| ng*h/mL | Empagliflozin/Linagliptin/Metformin FDC (Test) | Empagliflozin/Linagliptin/Metformin FC (Reference) |
|---|---|---|
| AUC(0-∞) for Metformin | 12745.62 ± 1.05 | 12724.27 ± 1.05 |
AUC(0-∞) for Linagliptin
| nmol*h/L | Empagliflozin/Linagliptin/Metformin FDC (Test) | Empagliflozin/Linagliptin/Metformin FC (Reference) |
|---|---|---|
| AUC(0-∞) for Linagliptin | 384.27 ± 1.05 | 394.95 ± 1.05 |
Collected over All adverse events (AEs) which occurred through the treatment phase and throughout the residual effect period (REP); up to 50 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Empagliflozin/Linagliptin/Metformin FDC (Test) | 0/29 (0%) | 0/29 (0%) | 11/29 (37.9%) |
| Empagliflozin/Linagliptin/Metformin FC (Reference) | 0/29 (0%) | 0/29 (0%) | 6/29 (20.7%) |
| Event | Empagliflozin/Linagliptin/Metformin FDC (Test) | Empagliflozin/Linagliptin/Metformin FC (Reference) |
|---|---|---|
| HeadacheNervous system disorders | 8/29 | 2/29 |
| NauseaGastrointestinal disorders | 1/29 | 2/29 |
| Oral herpesInfections and infestations | 2/29 | 0/29 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/29 | 2/29 |
Treated set (TS): This subject set included all subjects who were documented to have received one dose of study drug.
| Age, Continuous(years) | Test/ Reference (TR) | Reference/ Test (RT) | Total |
|---|---|---|---|
| Mean | 37.1 ± 12.2 | 43.5 ± 8.0 | 40.3 ± 10.7 |
| Sex: Female, Male(Participants) | Test/ Reference (TR) | Reference/ Test (RT) | Total |
|---|---|---|---|
| Female | 5 | 8 | 13 |
| Male | 10 | 7 | 17 |
| Race (NIH/OMB)(Participants) | Test/ Reference (TR) | Reference/ Test (RT) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 15 | 15 | 30 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2017 to primary completion in Nov 2017, 2 months.
Results were first posted in Feb 2020, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Empagliflozin · Linagliptin · Metformin